• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ASO Author Reflections: Is Systemic Immune-Inflammation Index a Useful Biomarker After Resection of Extrahepatic Cholangiocarcinoma: Results from the U.S. Extrahepatic Biliary Malignancy Consortium.

作者信息

Toyoda Junya, Sahara Kota, Endo Itaru, Pawlik Timothy M

机构信息

Department of Gastroenterological Surgery, Yokohama City University School of Medicine, Yokohama, Japan.

Department of Surgery, Division of Surgical Oncology, The Ohio State University Wexner Medical Center and James Comprehensive Cancer Center, Columbus, OH, USA.

出版信息

Ann Surg Oncol. 2022 Nov;29(12):7615-7616. doi: 10.1245/s10434-022-12105-y. Epub 2022 Jul 1.

DOI:10.1245/s10434-022-12105-y
PMID:35776259
Abstract
摘要

相似文献

1
ASO Author Reflections: Is Systemic Immune-Inflammation Index a Useful Biomarker After Resection of Extrahepatic Cholangiocarcinoma: Results from the U.S. Extrahepatic Biliary Malignancy Consortium.ASO作者反思：全身免疫炎症指数在肝外胆管癌切除术后是否是一个有用的生物标志物：来自美国肝外胆管恶性肿瘤联盟的结果。
Ann Surg Oncol. 2022 Nov;29(12):7615-7616. doi: 10.1245/s10434-022-12105-y. Epub 2022 Jul 1.
2
Extrahepatic cholangiocarcinoma: current surgical strategy.肝外胆管癌：当前的手术策略
Surg Oncol Clin N Am. 2009 Apr;18(2):269-88, viii. doi: 10.1016/j.soc.2008.12.003.
3
ASO Author Reflections: Development and Validation of Distal Cholangiocarcinoma Early Recurrence (DICER) Score: Results from the US Extrahepatic Biliary Malignancy Consortium.ASO作者反思：远端胆管癌早期复发（DICER）评分的开发与验证：美国肝外胆管恶性肿瘤联盟的结果
Ann Surg Oncol. 2021 Aug;28(8):4214-4215. doi: 10.1245/s10434-021-09844-9. Epub 2021 Mar 21.
4
Mass-forming intrahepatic cholangiocarcinoma presenting tumor growth in extrahepatic bile duct and superficial spreading.肿块形成型肝内胆管癌表现为肝外胆管肿瘤生长及浅表扩散。
Hepatogastroenterology. 2003 Jan-Feb;50(49):21-3.
5
Left hemihepatectomy and caudate lobectomy and complete extrahepatic bile duct resection using transduodenal approach for hilar cholangiocarcinoma arsing from biliary papillomatosis.采用经十二指肠途径行左半肝切除术、尾状叶切除术及肝外胆管完全切除术治疗源于胆管乳头状瘤病的肝门部胆管癌。
J Surg Oncol. 2008 Aug 1;98(2):139-42. doi: 10.1002/jso.21089.
6
The current management of hilar cholangiocarcinoma.肝门部胆管癌的当前治疗方法
Adv Surg. 1999;33:345-73.
7
CD10+ fibroblasts are more involved in the progression of hilar/extrahepatic cholangiocarcinoma than of peripheral intrahepatic cholangiocarcinoma.CD10+ 纤维母细胞在肝门部/肝外胆管癌的进展中比在周围型肝内胆管癌中更为活跃。
Histopathology. 2009 Oct;55(4):423-31. doi: 10.1111/j.1365-2559.2009.03398.x.
8
Surgery of extrahepatic bile duct cancer - current evidence and recommendations.肝外胆管癌的外科治疗——当前证据与建议。
Rozhl Chir. 2022 Fall;101(9):416-420. doi: 10.33699/PIS.2022.101.9.416-420.
9
[Extrahepatic cholangiocarcinoma: current state of palliation therapy].[肝外胆管癌：姑息治疗的现状]
Zentralbl Chir. 2012 Dec;137(6):522-6. doi: 10.1055/s-0031-1283917. Epub 2012 Apr 17.
10
Confinement to the intrapancreatic bile duct is independently associated with a better prognosis in extrahepatic cholangiocarcinoma.局限于胰内胆管与肝外胆管癌较好的预后独立相关。
BMC Gastroenterol. 2016 Feb 24;16:21. doi: 10.1186/s12876-016-0444-1.

本文引用的文献

1
ASO Author Reflections: Development and Validation of Distal Cholangiocarcinoma Early Recurrence (DICER) Score: Results from the US Extrahepatic Biliary Malignancy Consortium.ASO作者反思：远端胆管癌早期复发（DICER）评分的开发与验证：美国肝外胆管恶性肿瘤联盟的结果
Ann Surg Oncol. 2021 Aug;28(8):4214-4215. doi: 10.1245/s10434-021-09844-9. Epub 2021 Mar 21.
2
Tumor Burden Dictates Prognosis Among Patients Undergoing Resection of Intrahepatic Cholangiocarcinoma: A Tool to Guide Post-Resection Adjuvant Chemotherapy?肿瘤负荷决定肝内胆管癌切除患者的预后：一种指导术后辅助化疗的工具？
Ann Surg Oncol. 2021 Apr;28(4):1970-1978. doi: 10.1245/s10434-020-09393-7. Epub 2020 Dec 1.
3
Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution.
胆管癌：一家机构对564例患者长达31年的经验总结。
Ann Surg. 2007 May;245(5):755-62. doi: 10.1097/01.sla.0000251366.62632.d3.